The company's new QuantStudio 5 Dx Real-Time PCR system allows users to wield multi-modal software to detect pathogens.
Under the terms of the deal, Siemens will expand its kPCR Molecular System menu to include Fast-track's range of tests covering several medical conditions.
The firm said the assay provides flexible automation and accurately identifies all six HCV genotypes as well as subtypes 1a and 1b.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The firm sees the new panel as an important step forward in its strategy to further penetrate the molecular diagnostics market with its qPCR products.
The test can detect the presence of the Zika virus, which is an earlier warning of infection than indicated by anti-Zika antibodies.
The deal gives Siemens Healthineers access to Neo New Oncology's next-generation sequencing-based assays and technology for tissue and biofluid specimens.
The companies will work together to pursue US Food and Drug Administration clearance for a workflow combining Siemens' sample prep module and Thermo's qPCR instrument.
The scientific products giants are exhibiting their combined workflow next week at the European Congress of Clinical Microbiology and Infectious Disease.
The firm also plans to launch its Versant MDx System sample prep module in the US next month for use with the test.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.